These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19299654)

  • 21. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
    Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
    Wu Y; Zehnle PMA; Rajak J; Koleci N; Andrieux G; Gallego-Villar L; Aumann K; Boerries M; Niemeyer CM; Flotho C; Bohler S; Erlacher M
    Leukemia; 2024 Jan; 38(1):136-148. PubMed ID: 37945692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
    Jiang YZ; Su GP; Dai Y; He HS; Huang LQ; Sun ZM; Huang DP
    Ann Clin Lab Sci; 2015; 45(5):598-601. PubMed ID: 26586716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
    Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
    Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
    [No Abstract]   [Full Text] [Related]  

  • 26. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.
    Aucagne R; Droin N; Paggetti J; Lagrange B; Largeot A; Hammann A; Bataille A; Martin L; Yan KP; Fenaux P; Losson R; Solary E; Bastie JN; Delva L
    J Clin Invest; 2011 Jun; 121(6):2361-70. PubMed ID: 21537084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
    Takahashi Y; Kimura S; Okano M
    Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology/Oncology.
    Honda Y; Tsuchida M; Zaike Y; Masunaga A; Yoshimi A; Kojima S; Ito M; Kikuchi A; Nakahata T; Manabe A
    Br J Haematol; 2014 Jun; 165(5):682-7. PubMed ID: 24588411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
    Oki Y; Jelinek J; Shen L; Kantarjian HM; Issa JP
    Blood; 2008 Feb; 111(4):2382-4. PubMed ID: 18055864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
    Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
    Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
    [No Abstract]   [Full Text] [Related]  

  • 33. Disappearance of minimal residual disease after the early withdrawal of immunosuppressants in a patient with juvenile myelomonocytic leukemia.
    Yanagisawa R; Matsuda K; Sakashita K; Nakazawa Y; Tanaka M; Saito S; Yoshikawa K; Kamijo T; Shiohara M; Koike K
    Pediatr Blood Cancer; 2011 Mar; 56(3):501-2. PubMed ID: 21225940
    [No Abstract]   [Full Text] [Related]  

  • 34. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
    Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
    Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 36. Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
    O'Halloran K; Ritchey AK; Djokic M; Friehling E
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28084675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation.
    Maschan M; Bobrynina V; Khachatryan L; Kalinina I; Solopova G; Avdonin P; Nasedkina T; Novichkova G; Maschan A
    Pediatr Blood Cancer; 2014 Oct; 61(10):1871-3. PubMed ID: 24590757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
    Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
    Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
    [No Abstract]   [Full Text] [Related]  

  • 39. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
    Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
    Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization.
    Serrao A; Loglisci G; Salaroli A; Zacheo I; Alimena G; Breccia M
    Leuk Lymphoma; 2013 Feb; 54(2):411-2. PubMed ID: 22694794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.